As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

Women who use an oral contraceptive might want to consider using a back-up method after starting a weight loss drug.

And while buzzy weight loss drugs like Ozempic, Mounjaro, and Wegovy have relied on weekly injections, new oral medication pills made with the same active ingredient, semaglutide, could soon enter ...

And while buzzy weight loss drugs like Ozempic, Mounjaro, and Wegovy have relied on weekly injections, new oral medication pills made with the same active ingredient, semaglutide, could soon enter ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

The pill version of semaglutide was shown to be effective for weight loss. Drugs used for diabetes and weight loss like Ozempic and Wegovy were found to be effective for weight loss when taken as ...

Semaglutide was originally developed as a second-line treatment for type-2 diabetes. It’s marketed as Ozempic. There is now an Ozempic pill soon to be released. The pill form Semaglutide weight loss ...

Novo Nordisk, which makes the blockbusters Ozempic for diabetes and Wegovy for weight loss, both based on the same medication generically called semaglutide, presented two new studies on a pill ...

The study was funded by Eli Lilly. Pfizer has also tested its own pill in that drug class. Oral semaglutide is not new: There’s already a tablet form of the compound on the market, sold under ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill from Eli Lilly could be as effective for weight loss and blood sugar ...

Significantly more people with overweight or obesity treated with high-dose semaglutide pills also achieved clinically significant weight loss versus placebo, the trial's other co-primary endpoint ...

A once-daily pill version of the drug popularly known as Ozempic is one step closer to market. Drugmaker Novo Nordisk announced the results of a large, phase 3 trial of oral semaglutide on Monday.